DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0054688A1 May Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0054688A1 May Et Al US 2005.0054688A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0054688A1 May et al. (43) Pub. Date: Mar. 10, 2005 (54) SELECTIVE SEROTONN REUPTAKE Related U.S. Application Data INHIBITORS IN THE TREATMENT OF DISEASE (60) Provisional application No. 60/528,136, filed on Dec. 9, 2003. (75) Inventors: Kathryn Elizabeth May, County of Kent (GB); Paul Quinn, County of (30) Foreign Application Priority Data Kent (GB) Aug. 8, 2003 (GB)......................................... O3187O6.9 Correspondence Address: PFIZER INC. Publication Classification PATENT DEPARTMENT, MS8260-1611 EASTERN POINT ROAD (51) Int. Cl." ......................... A61K 31/44; A61K 31/18; GROTON, CT 06340 (US) A61K 31/137 (52) U.S. Cl. ........................... 514/345; 514/602; 514/649 (73) Assignee: Pfizer Inc (57) ABSTRACT (21) Appl. No.: 10/911,806 The present invention provides the use of Selective Serotonin reuptake inhibitors (SSRIs) to treat premature female (22) Filed: Aug. 5, 2004 Orgasm. US 2005/0054688A1 Mar. 10, 2005 SELECTIVE SEROTONIN REUPTAKE 0009 b) Interpersonal difficulties arise from female INHIBITORS IN THE TREATMENT OF DISEASE lack of motivation for/discomfort with continued Sexual Stimulation. 0001. This application claims priority from United King dom Application Number 0318706.9, filed on Aug. 8, 2003 0010 c) The disturbance gives rise to negative psy and the benefit of U.S. Provisional Application No. 60/528, chosocial consequences where arousal occurs in 136, filed on Dec. 9, 2003. inappropriate situations 0002 This invention relates to the use of compounds 0011 d) The disturbance itself causes marked dis which exhibit activity as Selective Serotonin re-uptake treSS or interpersonal difficulty inhibitors (SSRIs) to treat premature female orgasm, and to 0012. According to a first aspect, the invention provides pharmaceutical formulations containing Such compounds. for a Selective Serotonin reuptake inhibitor in the preparation 0003) Whilst anorgasmia and difficulties with orgasm are of a medicament for the treatment or prevention of prema well-represented in the female Sexual dysfunction literature, ture female orgasm. rapid orgasm-a female problem, Sharing components with 0013 By SSRI it is meant a compound with a serotonin premature ejaculation (PE) in men—is notable by its re-uptake inhibition (SRI) ICso value of less than or equal to absence. DSMIVR (2000) includes no mention of it, 100 nM. Preferred compounds have a serotonin re-uptake although it has an otherwise comprehensive Section on inhibition (SRI) ICso value of less than or equal to 50 nM. orgasmic disorders. Particularly preferred compounds have a Serotonin re-uptake inhibition (SRI) ICso value of less than or equal to 10 nM. 0004. It has been suggested that the distribution curve for female orgasm is likely to be very similar to that used to 0014. In a preferred embodiment the compounds are describe male experience (Cole and Dryden, 1988). How more than 10-fold as potent in the inhibition of serotonin ever, both clinically and in the research and its literature, the re-uptake than in the inhibition of dopamine re-uptake, retarded as opposed to the premature end of this is very preferred compounds are more than 100-fold as potent, much the focus of interest. This weighting is also Strongly particularly preferred compounds are more than a 1000-fold reflected in cases Seen, with cases of rapid orgasm in women as potent. presenting rarely and representing a far Smaller percentage 0015. In a preferred embodiment the compounds are of the female caseload than the 30% or more of male more than 10-fold as potent in the inhibition of serotonin caseload taken by PE. This is partly because male partners re-uptake than in the inhibition of noradrenaline re-uptake, often choose to take rapid orgasm as positive feedback on preferred compounds are more than 100-fold as potent, their skill as a lover and partly because, generally Speaking, particularly preferred compounds are more than a 1000-fold it presents fewer problems in terms of continuing with as potent. intercourse than PE. This is particularly So where the female partner is multi-orgasmic and therefore potentially well 0016 Particularly suitable SSRIs for use in treating pre motivated to continue. mature female orgasm may be characterised by having a rapid onset and a short duration of action. 0005. Unfortunately, a proportion of women with rapid orgasm find continued post-orgasmic Stimulation uncom 0017 Suitable SSRIs for use in the present invention include: Sertraline, fluoxetine, fluvoxamine, paroxetine, cit fortable, if not painful. This group has no wish to continue allopram, dapoxetine, 3-(dimethylamino)methyl-4-4-(me with intercourse, having reached orgasm, and indeed may thylsulfanyl)phenoxybenzenesulfonamide (Example 28, feel unable to do so. This tends to give rise to interpersonal WO 0172687), 3-(dimethylamino)methyl-4-3-methyl-4- distress, which is difficult to resolve and these tend to be the (methylsulfanyl)phenoxybenzenesulfonamide (Example couples referred to Sex Therapy Clinics and gynaecology. 12, WO 0218333), N-methyl-N-({3-3-methyl-4-(methyl The problem of disengagement of the female partner is also Sulfanyl)phenoxy-4-pyridinyl)methyl)amine (Example 38, reported, with males feeling incidental or rejected, in the PCT Application no PCT/IB02/01032), methyl-3-(4-meth same way as female partners of men with PE. ylsulfanyl-phenoxy)-pyridin-4-ylmethylamine (Example 0006 Cognitive/behavioural treatments are more difficult 35 WO02/083643), Escitalopram, Litoxetine, 403U76, to describe and implement than in PE, the arousal element VN-2222, Roxindle, Milnacipran, RS-1439, R-fluoxetine, of the Human Sexual Response curve being So attenuated WF-32, DOV-216303, LY-393558, LY-433221, Cer that women find it immensely difficult to assert any kind of iclamine, UP-23761, Indalpine, YM-992/Lubazodone, control. Whilst men with PE are educated to recognise the A-80426, Nefazodone, DuP-631, Biciifadine, Duloxetine, point of ejaculatory inevitability, a corresponding point of LY-214821, LY-393558, LU-10134-C, Sibutramine, SPD orgasmic inevitability is not identified and intervention to 473, Tramadol, CI-275838, McN-5652, L792239, Vilaz disrupt it would anyway presumably prove to be problem odone, NS-2359, NS-2381, ORG-6582, Femoxetine, atic. The adoption of other treatment Strategies used in PE RS-1259, R-DDMS, S-Sibutramine, S-fluoxetine, Dexen (SS cream, local anaesthetics, SSRIs) is not reported in the furamine, S-34324, Du-125530, SLV-210, SLV-313, SLV Small available literature on rapid orgasm in Women. 314 and Venlafaxine. 0018 Preferred SSRIs are sertraline, fluoxetine, fluvox 0007 Premature female orgasm may be defined as: amine, paroxetine, citalopram, dapoxetine, 3-(dimethy 0008 a) Persistent or recurrent orgasm with mini lamino)methyl-4-4-(methylsulfanyl)phenoxybenzene mal Sexual Stimulation, occurring before, upon or Sulfonamide (Example 28, WO 0172687), Shortly after penetration and generally before the 3-(dimethylamino)methyl-4-3-methyl-4-(methylsulfa perSon/couple wishes it. nyl)phenoxybenzenesulfonamide (Example 12, WO US 2005/0054688A1 Mar. 10, 2005 0218333), methyl-3-(4-methylsulfanyl-phenoxy)-pyridin H-Dopamine substrates. All reactions were carried out at 4-ylmethylamine (Example 35 WO02/083643), N-methyl room temperature in a shaking incubator. Incubation times N-(3-3-methyl-4-(methylsulfanyl)phenoxy-4- were 5 minutes for the hSERT and hDAT assays and 15 pyridinyl)methyl)amine (Example 38, PCT Application no minutes for the hNET assay. Reactions were terminated by PCT/IB02/01032). removal of the reaction mixture using a vacuum manifold 0019 More preferred SSRIs are 3-(dimethylamino)m- followed by rapid washing with ice cold assay buffer. The ethyl-4-4-(methylsulfanyl)phenoxybenzenesulfonamide quantity of H-substrate incorporated into the cells was then (Example 28, WO 0172687), 3-(dimethylamino)methyl-4- quantified. 3-methyl-4-(methylsulfanyl)phenoxybenzenesulfonamide 0030 Assay plates were dried in a microwave oven, (Example 12, WO 0218333), methyl-3-(4-methylsulfanyl Scintillation fluid added, and radioactivity measured. phenoxy)-pyridin-4-ylmethylamine (Example 35 WO02/ Potency of test compounds was quantified as ICso values 083643), N-methyl-N-(3-3-methyl-4-(methylsulfa (concentration of test compound required to inhibit the nyl)phenoxy-4-pyridinyl)methyl)amine (Example 38, PCT specific uptake of radiolabelled substrate into the cells by Application no PCT/IB02/01032), paroxetine and dapoxet 50%). C. 0031 (iii) Standard Assay Buffer Composition: 0020 Yet more preferred are 3-(dimethylamino)m- ethyl-4-4-(methylsulfanyl)phenoxybenzenesulfonamide 0.032 Trizma hydrochloride (26 mM) (Example 28, WO 0172687), 3-(dimethylamino)methyl-4- 0033 NaCl (124 mM) 3-methyl-4-(methylsulfanyl)phenoxybenzenesulfonamide (Example 12, WO 0218333), methyl-3-(4-methylsulfanyl 0034). KCl (4.5 mM) phenoxy)-pyridin-4-ylmethylamine (Example 35 WO02/ 0035). KHPO (1.2 mM) 083643), N-methyl-N-(3-3-methyl-4-(methylsulfa nyl)phenoxy-4-pyridinyl)methyl)amine (Example 38, PCT 0036) MgCl,.6HO (1.3 mM) Application no PCT/IB02/01032). 0037 Ascorbic acid (1.136 mM) 0021. The text of the aforementioned patents and all other 0038 Glucose (5.55 mM) references cited in this Specification are hereby incorporated by reference in their entirety. 0039 pH 7.40 0022. It should be understood that compounds suitable 0040 CaCl (2.8 mM) for use in the present invention, as exemplified above or as 0041 Pargyline (100 uM) identified by the assays described herein, may encompass pharmaceutically acceptable Salts, Solvates and prodrugs 0042. Note: The pH of the buffer was adjusted to 7.40 thereof. with 1M NaOH before addition of CaCl and pargyline. 0023 Compounds suitable for use as an SSRI may be 0043 (iv) Summary of Assay Parameters identified by the use of the following assay: 0024 Biological Activity hSERT hDAT hNET 0.025 Compounds may be tested for their ability to Assay Assay Assay inhibit the uptake of Serotonin by human Serotonin trans Cell concentration per 75,000 75,000 75,000 porters, dopamine by human dopamine transporters or assay well.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,580,832 B2 Gaul Et Al
    USOO858O832B2 (12) United States Patent (10) Patent No.: US 8,580,832 B2 Gaul et al. (45) Date of Patent: Nov. 12, 2013 (54) SUBSTITUTED PHENOXY Pacifici, R.J., “Estrogen, Cytokines, and Pathogenesis of AMINOTHAZOLONES AS ESTROGEN Postmenopausal Osteoporosis.”. Bone Miner. Res., 1996, vol. 11 (8), RELATED RECEPTOR-O MODULATORS pp. 1043-1051. International Search Report, PCT/US2008/056029, date of mailing (75) Inventors: Michael Gaul, Yardley, PA (US); of International Search Repont, Jul. 4, 2008. Alexander Kim, Levittown, PA (US); Written Opinion relating to PCT/US2008/056029. Lily Lee Searle, Waltham, MA (US); Strum et al., “Rosiglitazone Induces Mitochondrial Biogenesis in Dionisios Rentzeperis, Downingtown, Mouse Brain”, Journal of Alzheimer's Disease, 2007, vol. 11(1), pp. PA (US); Gilles C. Bignan, Brigewater, 45-51, IOS Press, Asterdam, NL. NJ (US) Grundy, S., et al. “Definition of Metabolic Syndrome'. Circulation 2004:109:433-438. (73) Assignee: Janssen Pharmaceutica N.V. (BE) Kamei, Y, et al. “PPARY Coactivator 13/ERR Ligand 1 is an ERR Protein Ligand, Whose Expression Induces a High-Energy Expendi (*) Notice: Subject to any disclaimer, the term of this ture and Antagonizes Obesity”, PNAS, vol. 100, No. 21, 2003, pp. patent is extended or adjusted under 35 12378-12383. U.S.C. 154(b) by 768 days. Jones, P. et al. “N-CoR-HDAC Corepressor Complexes: Roles in Transcriptional Regulation by Nuclear Hormone Receptors', Chap (21) Appl. No.: 12/043,311 ter 9, Curr. Top. Microbiol. Immunol. 2003, 274, pp. 237-268. Luo, J., et al. “Reduced Fat Mass in Mice Lacking Orphan Nuclear (22) Filed: Mar.
    [Show full text]
  • Evaluation of Antidepressant-Related Behavioral Responses in Mice Lacking the Serotonin Transporter Andrew Holmes, Rebecca J
    Evaluation of Antidepressant-related Behavioral Responses in Mice Lacking the Serotonin Transporter Andrew Holmes, Rebecca J. Yang, Dennis L. Murphy, and Jacqueline N. Crawley Inhibition of the serotonin transporter (5-HTT) is a 5-HTT Ϫ/Ϫ mice on the C57BL/6J background showed no principal initial target of many antidepressants. However, baseline antidepressant-related phenotype on either test. the contribution of the 5-HTT to their therapeutic efficacy is The behavioral effects of three antidepressants were tested in incompletely understood. We utilized a targeted gene 5-HTT mutant mice (C57BL/6J background) in the tail mutation approach to examine the role of the 5-HTT in the suspension test. The anti-immobility effects of the serotonin behavioral actions of antidepressants. The 5-HTT mutation reuptake inhibitor, fluoxetine (30 mg/kg), were abolished in was bred onto two separate genetic backgrounds, C57BL/6J 5-HTT Ϫ/Ϫ mice, confirming that the 5-HTT gene is and 129S6. On a preliminary screen for gross physical, required for the behavioral effects of fluoxetine. In contrast, neurological and behavioral functions, all measures were 5-HTTϪ/Ϫ mice retained sensitivity to the anti-immobility normal with the exception that 5-HTT Ϫ/Ϫ mice on the effects of the norepinephrine reuptake inhibitor, desipramine C57BL/6J background showed increased body weight and (20 mg/kg), and the mixed serotonin/norepinephrine poor rotarod performance, and 5-HTT Ϫ/Ϫ mice on the reuptake inhibitor, imipramine (25 mg/kg). 5-HTT 129S6 background showed reduced neuromuscular knockout mice provide a valuable tool for delineating the strength. On the tail suspension test, 5-HTT Ϫ/Ϫ mice on neuropsychopharmacological actions of antidepressants.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • The Evidence Report
    Obesity Education Initiative C LINICAL GUIDELINES ON THE IDENTIFICATION, EVALUATION, AND TREATMENT OF OVERWEIGHT AND OBESITY IN ADULTS The Evidence Report NATIONAL INSTITUTES OF HEALTH NATIONAL HEART, LUNG, AND BLOOD INSTITUTE C LINICAL GUIDELINES ON THE IDENTIFICATION, EVALUATION, AND TREATMENT OF OVERWEIGHT AND OBESITY IN ADULTS The Evidence Report NIH PUBLICATION NO. 98-4083 SEPTEMBER 1998 NATIONAL INSTITUTES OF HEALTH National Heart, Lung, and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults F. Xavier Pi-Sunyer, M.D., M.P.H. William H. Dietz, M.D., Ph.D. Chair of the Panel Director Chief, Endocrinology, Diabetes, and Nutrition Division of Nutrition and Physical Activity Director, Obesity Research Center National Center for Chronic Disease Prevention St. Luke's/Roosevelt Hospital Center and Health Promotion Professor of Medicine Centers for Disease Control and Prevention Columbia University College of Physicians and Atlanta, GA Surgeons New York, NY John P. Foreyt, Ph.D. Professor of Medicine and Director Diane M. Becker, Sc.D., M.P.H. Nutrition Research Clinic Director Baylor College of Medicine Center for Health Promotion Houston, TX Associate Professor Department of Medicine Robert J. Garrison, Ph.D. The Johns Hopkins University Associate Professor Baltimore, MD Department of Preventive Medicine University of Tennessee, Memphis Claude Bouchard, Ph.D. Memphis, TN Professor of Exercise Physiology Physical Activity Sciences Scott M. Grundy, M.D., Ph.D. Laboratory Director Laval University Center for Human Nutrition Sainte Foy, Quebec University of Texas CANADA Southwestern Medical Center at Dallas Dallas, TX Richard A.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Newer Generation Antidepressants for Depressive Disorders in Children and Adolescents (Review)
    Newer generation antidepressants for depressive disorders in children and adolescents (Review) Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 11 http://www.thecochranelibrary.com Newer generation antidepressants for depressive disorders in children and adolescents (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 12 Figure1. ..................................... 14 Figure2. ..................................... 21 Figure3. ..................................... 22 Figure4. ..................................... 24 Figure5. ..................................... 25 Figure6. ..................................... 26 Figure7. ..................................... 27 Figure8. ..................................... 29 DISCUSSION ..................................... 36 AUTHORS’CONCLUSIONS . 40 ACKNOWLEDGEMENTS . 41 REFERENCES ..................................... 42 CHARACTERISTICSOFSTUDIES . 52 DATAANDANALYSES. 114 ADDITIONALTABLES. 116 WHAT’SNEW....................................
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Desmethylene Paroxetine (hydrochloride) Item No. 15908 CAS Registry No.: 1394861-12-1 Formal Name: 4-[[(3S,4R)-4-(4-fluorophenyl)- H 3-piperidinyl]methoxy]-1,2- N benzenediol, monohydrochloride OH MF: C18H20FNO3 • HCl FW: 353.8 ≥98% Purity: F O OH Supplied as: A crystalline solid • HCl Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Desmethylene paroxetine (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the desmethylene paroxetine (hydrochloride) in the solvent of choice. Desmethylene paroxetine (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of desmethylene paroxetine (hydrochloride) in ethanol and DMSO is approximately 20 mg/ml and approximately 30 mg/ml in DMF. Description Paroxetine (Item No. 14998) is a potent, selective serotonin reuptake inhibitor (Ki = 0.72 nM) that has been used in cases of depression and anxiety disorder.1-3 Desmethylene paroxetine is a major urinary metabolite of paroxetine.4,5 This compound may be used in urine drug testing applications involving paroxetine toxicology or forensic analysis. References 1. Mattson, R.J., Catt, J.D., Denhart, D.J., et al. Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors. J. Med. Chem. 48(19), 6023-6034 (2005). 2. Baldwin, D., Woods, R., Lawson, R., et al. Efficacy of drug treatments for generalised anxiety disorder: Systematic review and meta-analysis. BMJ 342, d1199 (2011). 3.
    [Show full text]
  • An Inventory of Literature on the Relation Between Drug Use, Impaired Driving and Traffic Accidents
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by National Documentation Centre on Drug Use E.M.C.D.D.A. DRUGS MISUSE RESEARCH DIVISION HEALTH RESEARCH BOARD An Inventory of Literature on the Relation between Drug Use, Impaired Driving and Traffic Accidents CT.97.EP.14 Research Team: Colin Gemmell Trinity College, Dublin Rosalyn Moran Drugs Misuse Research Division, Health Research Board James Crowley Professor, Transport Policy Research Institute, University College Dublin Richeal Courtney Medical Expert, for the Health Research Board EMCDDA: Lucas Wiessing February 1999 Please use the following citation: European Monitoring Centre for Drugs and Drug Addiction. An Inventory of Literature on the Relation betweenDrug Use, Impaired Driving and Traffic Accidents. (CT.97.EP.14) Lisbon: EMCDDA, February 1999. Contact Details Drugs Misuse Research Division Health Research Board 73 Lower Baggot Street Dublin 2 Ireland European Monitoring Centre for Drugs and Drug Addiction Rua Cruz de Santa Apolónia 23/25 1100, Lisboa Portugal. Further copies of this bibliography can be obtained from the EMCDDA at the above address. CREDITS Principal Researchers Ms Rosalyn Moran, Project Leader, Health Research Board Professor James Crowley, Professor, Transport Policy Research Institute, UCD Dr Richeal Courtney, Medical Expert, on behalf of the Health Research Board Research Assistants Colin Gemmell (Synthesis and Final Reports) Sarah Heywood (Literature Search and Collaborative Network) For the EMCDDA Lucas Wiessing
    [Show full text]